Skip to main content

Comprehensive characterization and effective combinatorial targeting of high-grade serous ovarian cancer via single-cell analysis

Objective

The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient.

This project takes an advantage on prospectively and longitudinally collected fresh sample specimens from multiple anatomic sites of HGS-OvCa patients with metastatic disease. Fluorescence activated cell sorting and recently developed mass cytometry are used to identify subpopulations in HGS-OvCa tumors. This is followed by single-cell analysis at genetic and transcriptomics levels, and ex vivo drug screening experiments. These data will be used to establish network models to predict the most effective combinatorial treatments. The key results will be validated with existing HGS-OvCa data together with prospective and retrospective cohorts and in vivo models. The clinically most actionable treatment suggestions from our
modelling efforts will be translated to HGS-OvCa patient care.

Ovarian cancer kills more than 40,000 women in Europe every year due to lack of effective and long-lasting therapeutic regimens. HERCULES presents an innovative strategy to suggest effective treatments that lead to a marked decrease in ovarian cancer deaths and reduce the number of expensive but inefficient treatments. Our approach paves the way to move beyond the current trial-and-error clinical assessment of drug combinations toward more systematic prediction of the most effective drug combinations for each patient. The proposed approach will be a major breakthrough in systems medicine and will benefit individual ovarian cancer patients and the health-care system through more effective treatments, and the
diagnostic and pharmaceutical industry through tools for better stratified clinical trials, and novel treatment and diagnostic modalities.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

HELSINGIN YLIOPISTO
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Finland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 444 812,50

Participants (8)

VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA
Finland
EU contribution
€ 297 312,50
Address
Kiinamyllynkatu 4-8
20520 Turku
Activity type
Research Organisations
TURUN YLIOPISTO
Finland
EU contribution
€ 999 211,25
Address
Yliopistonmaki
20014 Turku
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI TRIESTE
Italy
EU contribution
€ 350 000
Address
Piazzale Europa 1
34127 Trieste
Activity type
Higher or Secondary Education Establishments
ISTITUTO SUPERIORE DI SANITA
Italy
EU contribution
€ 356 250
Address
Viale Regina Elena 299
00161 Roma
Activity type
Research Organisations
KAROLINSKA INSTITUTET

Participation ended

Sweden
EU contribution
€ 332 712,24
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
INSTITUT PASTEUR
France
EU contribution
€ 360 101,25
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
AB ANALITICA SRL
Italy
EU contribution
€ 287 500
Address
Via Svizzera 16
35127 Padova
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 566 969,01
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments